ABBV-8E12
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Supranuclear Palsy (PSP)
Conditions
Progressive Supranuclear Palsy (PSP)
Trial Timeline
Apr 17, 2018 → Nov 20, 2019
NCT ID
NCT03413319About ABBV-8E12
ABBV-8E12 is a phase 1 stage product being developed by AbbVie for Progressive Supranuclear Palsy (PSP). The current trial status is completed. This product is registered under clinical trial identifier NCT03413319. Target conditions include Progressive Supranuclear Palsy (PSP).
What happened to similar drugs?
2 of 20 similar drugs in Progressive Supranuclear Palsy (PSP) were approved
Approved (2) Terminated (4) Active (14)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03744546 | Pre-clinical | Completed |
| NCT03413319 | Phase 1 | Completed |
Competing Products
20 competing products in Progressive Supranuclear Palsy (PSP)